GENinCode UK Ltd. (9PL) Stock Price & Analysis
9PL Stock Chart & Stats
- Day’s Range
- EUR 0.01 - EUR 0.01
- 52-Week Range
- EUR 0.01 - EUR 0.08
- Previous Close
- EUR 0.01
- Volume
- N/A
- Average Volume (3M)
- 0
- Market Cap
- EUR 5.96M
- Enterprise Value
- EUR 4.24M
- Total Cash (Recent Filing)
- EUR 2.05M
- Total Debt (Recent Filing)
- EUR 98.00K
- Price to Earnings (P/E)
- ―
- Beta
- 13.27
- Next Earnings
- Jun 08, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Revenue Growth Acceleration
The reported acceleration in revenue growth indicates improving commercial traction and a larger opportunity to leverage the existing business platform. If sustained, stronger top-line expansion can help spread fixed costs, support operating improvement, and increase the potential for future scale benefits.
Modest Absolute Debt
Small absolute debt reduces the immediate burden of principal and interest obligations compared with a heavily leveraged balance sheet. This provides some financial flexibility while the company works to improve profitability, although the benefit is constrained by its continuing losses and reduced equity.
Gross Margin Improvement
Higher gross margin shows that the company is retaining more value from each unit of revenue than it did previously. Continued margin improvement could strengthen the economics of growth and provide a more credible path toward covering operating costs as revenue expands.
Bears Say
Deep Unprofitability
Extremely negative net, EBIT, and EBITDA margins show that current revenue is far below the level needed to support the cost base. Persistent operating losses weaken internal funding capacity and make profitability dependent on substantial improvement in scale, efficiency, or both.
Persistent Cash Burn
Recurring negative operating and free cash flow indicate that the business has not yet converted its activities into self-funding operations. Continued cash burn can consume financial resources, increase dependence on external funding, and limit investment capacity over the coming quarters.
Sharp Equity Erosion
The steep decline in equity materially reduces the balance sheet cushion available to absorb further losses. Even with modest total debt, weaker equity increases financial risk, narrows capital allocation flexibility, and makes continued cash losses more consequential.
GENinCode UK Ltd. News
9PL FAQ
What was GENinCode UK Ltd.’s price range in the past 12 months?
What is GENinCode UK Ltd.’s market cap?
When is GENinCode UK Ltd.’s upcoming earnings report date?
How were GENinCode UK Ltd.’s earnings last quarter?
Is GENinCode UK Ltd. overvalued?
Does GENinCode UK Ltd. pay dividends?
What is GENinCode UK Ltd.’s EPS estimate?
How many shares outstanding does GENinCode UK Ltd. have?
What happened to GENinCode UK Ltd.’s price movement after its last earnings report?
Which hedge fund is a major shareholder of GENinCode UK Ltd.?
What is the TipRanks Smart Score and how is it calculated?
Company Description
GENinCode UK Ltd.
GENinCode Plc specializes in the creation and commercialization of advanced genetic tests designed to forecast potential health risks based on an individual's DNA. Operating in both the United Kingdom and internationally, their predictive technology empowers individuals and medical professionals alike with proactive health management and targeted intervention strategies. The company's sophisticated molecular diagnostics leverage a combination of clinical algorithms and artificial intelligence to deliver precise patient risk assessments, thereby anticipating the onset of various diseases. Among their specialized tests are: Cardio inCode: A patented genetic assay designed to guide individuals in cardiovascular prevention. Lipid inCode: A genetic diagnostic tool that analyzes seven specific genes associated with familial hypercholesterolemia. SUDD inCode: A genetic test to identify the underlying causes of sudden cardiac death and inherited heart conditions. Thrombo inCode: This test assesses 12 genetic variants linked to hereditary thrombophilia and the general risk of thrombosis (blood clots). Thrombo inCode Reproductive Health: Offering crucial insights into thrombophilia risks particularly relevant to prospective pregnancies. Established in 2018, GENinCode Plc maintains its headquarters in Oxford, United Kingdom.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Matthew Heaton Walls
- Employees
- 44
- Website
- www.genincode.com
- Address
- One St. Peters Square, Manchester, GM, M2 3DE, GB
GENinCode UK Ltd. (9PL) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 3 | 3 | 14 |
| Technical Analysis | 3 | 3 | 4 |
| Moving Averages | 0 | 0 | 10 |










